Nexgel (NXGLW) EBT (2018 - 2026)

Nexgel (NXGLW) has reported EBT for 9 consecutive years, with -$3.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 463.44% year-over-year to -$3.6 million; the trailing twelve-month figure through Jun 2026 stood at -$5.8 million (down 101.0% YoY), and the FY2025 full-year result was -$2.9 million, up 16.46% from the prior year.
• EBT eased to -$3.6 million in Q2 2026 per NXGLW's latest filing, from -$928000.0 in the prior quarter.
• Across five years, EBT topped out at -$552000.0 in Q3 2023 and bottomed at -$3.6 million in Q2 2026.
• Historically, EBT has averaged -$1.1 million across 5 years, with a median of -$824000.0 in 2024.
• The sharpest annual moves came in 2022 and 2026: EBT surged 63.29% in 2022, then slumped 463.44% in 2026.
• Over 5 years, EBT stood at -$648000.0 in 2022, then plunged by 83.18% to -$1.2 million in 2023, then jumped by 30.58% to -$824000.0 in 2024, then decreased by 12.62% to -$928000.0 in 2025, then sank by 288.58% to -$3.6 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$3.6 million, -$928000.0, and -$647000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.